CP-601932 selectively reduces ethanol consumption following chronic exposure without affecting sucrose consumption or operant self-administration; it is a high-affinity partial agonist of α3β4 nicotinic acetylcholine receptors (nAChRs) with potential therapeutic application in the treatment of alcohol use disorders.